Non-coding RNAs in Cardiac Regeneration: Mechanism of Action and Therapeutic Potential
Overview
Reproductive Medicine
Affiliations
In the past two decades, thousands of non-coding RNAs (ncRNAs) have been discovered, annotated, and characterized in nearly every tissue under both physiological and pathological conditions. Here, we will focus on the role of ncRNAs, including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs) in ischemic heart disease (IHD), which remains the leading cause of morbidity and mortality in humans-resulting in 8.9 million deaths annually. Cardiomyocyte (CM) proliferation, differentiation, and survival in addition to neovascularization of injured tissues and the prevention of fibrosis are commonly regarded as critically important for the recovery of the heart following myocardial infarction (MI). An abundance of evidence has been accumulated to show ncRNAs participate in cardiac recovery after MI. Because miRNAs are important regulators of cardiac regeneration, the therapeutic potential of at least five of these molecules has been assessed in large animal models of human IHD. In particular, miRNA-based interventions based on miR-132 and miR-92a inhibition in related diseases have displayed favorable outcomes that have provided the impetus for miRNA-based clinical trials for IHD. At the same time, the functional roles of lncRNAs and circRNAs in cardiac regeneration are also being explored. In the present review, we will summarize the latest ncRNA studies aimed at reversing damage to the ischemic heart and discuss the therapeutic potential of targeting miRNAs, lncRNAs, and circRNAs to stimulate cardiac regeneration.
Sanchez V, Harel S, Saub A, Mayaki D, Hussain S Cells. 2025; 14(2).
PMID: 39851503 PMC: 11763389. DOI: 10.3390/cells14020075.
In-depth analysis of lupeol: delving into the diverse pharmacological profile.
Dalimunthe A, Carensia Gunawan M, Dhiya Utari Z, Dinata M, Halim P, Estherina S Pakpahan N Front Pharmacol. 2024; 15:1461478.
PMID: 39605919 PMC: 11598436. DOI: 10.3389/fphar.2024.1461478.
Shan T, Yang T, Jing P, Bao Y, Zhou L, Zhu T Research (Wash D C). 2024; 7:0451.
PMID: 39193132 PMC: 11347128. DOI: 10.34133/research.0451.
Therapeutic Inhibition of Protects Against Cardiac Hypertrophy.
Wang Y, Zhang M, Wang R, Lin J, Ma Q, Guo H Circ Res. 2024; 135(3):434-449.
PMID: 38864216 PMC: 11257812. DOI: 10.1161/CIRCRESAHA.123.323356.
Jiang H, Lai F, Wang X, Meng F, Zhu W, Huang S ESC Heart Fail. 2024; 11(5):2869-2880.
PMID: 38714309 PMC: 11424367. DOI: 10.1002/ehf2.14823.